BACKGROUND: Cerebrospinal fluid (CSF) and neuroimaging abnormalities demonstrate neuronal injury during chronic AIDS, but data on these biomarkers during primary human immunodeficiency virus (HIV) infection is limited. METHODS: We compared CSF concentrations of neurofilament light chain, t-tau, p-tau, amyloid precursor proteins, and amyloid-beta 42 in 92 subjects with primary HIV infection and 25 controls. We examined relationships with disease progression and neuroinflammation, neuropsychological testing, and proton-magnetic resonance spectroscopy (MRS)-based metabolites. RESULTS: Neurofilament light chain was elevated in primary HIV infection compared with controls (P = .0004) and correlated with CSF neopterin (r = 0.38; P = .0005), interferon gamma-induced protein 10 (r = 0.39; P = .002), white blood cells (r = 0.32; P = .004), protein (r = 0.59; P < .0001), and CSF/plasma albumin ratio (r = 0.60; P < .0001). Neurofilament light chain correlated with decreased N-acteylaspartate/creatine and glutamate/creatine in the anterior cingulate (r = -0.35, P = .02; r = -0.40, P = .009, respectively), frontal white matter (r = -0.43, P = .003; r = -0.30, P = .048, respectively), and parietal gray matter (r = -0.43, P = .003; r = -0.47, P = .001, respectively). Beta-amyloid was elevated in the primary infection group (P = .0005) and correlated with time infected (r = 0.34; P = .003). Neither marker correlated with neuropsychological abnormalities. T-tau and soluble amyloid precursor proteins did not differ between groups. CONCLUSIONS: Elevated neurofilament light chain and its correlation with MRS-based metabolites suggest early neuronal injury in a subset of participants with primary HIV infection through mechanisms involving central nervous system inflammation.
BACKGROUND: Cerebrospinal fluid (CSF) and neuroimaging abnormalities demonstrate neuronal injury during chronic AIDS, but data on these biomarkers during primary human immunodeficiency virus (HIV) infection is limited. METHODS: We compared CSF concentrations of neurofilament light chain, t-tau, p-tau, amyloid precursor proteins, and amyloid-beta 42 in 92 subjects with primary HIV infection and 25 controls. We examined relationships with disease progression and neuroinflammation, neuropsychological testing, and proton-magnetic resonance spectroscopy (MRS)-based metabolites. RESULTS: Neurofilament light chain was elevated in primary HIV infection compared with controls (P = .0004) and correlated with CSF neopterin (r = 0.38; P = .0005), interferon gamma-induced protein 10 (r = 0.39; P = .002), white blood cells (r = 0.32; P = .004), protein (r = 0.59; P < .0001), and CSF/plasma albumin ratio (r = 0.60; P < .0001). Neurofilament light chain correlated with decreased N-acteylaspartate/creatine and glutamate/creatine in the anterior cingulate (r = -0.35, P = .02; r = -0.40, P = .009, respectively), frontal white matter (r = -0.43, P = .003; r = -0.30, P = .048, respectively), and parietal gray matter (r = -0.43, P = .003; r = -0.47, P = .001, respectively). Beta-amyloid was elevated in the primary infection group (P = .0005) and correlated with time infected (r = 0.34; P = .003). Neither marker correlated with neuropsychological abnormalities. T-tau and soluble amyloid precursor proteins did not differ between groups. CONCLUSIONS: Elevated neurofilament light chain and its correlation with MRS-based metabolites suggest early neuronal injury in a subset of participants with primary HIV infection through mechanisms involving central nervous system inflammation.
Authors: Margaret R Lentz; John P Kim; Susan V Westmoreland; Jane B Greco; Robert A Fuller; Eva M Ratai; Julian He; Prabhat K Sehgal; Elkan F Halpern; Andrew A Lackner; Eliezer Masliah; R Gilberto González Journal: Radiology Date: 2005-03-29 Impact factor: 11.105
Authors: Eva-Maria Ratai; Lakshmanan Annamalai; Tricia Burdo; Chan-Gyu Joo; Jeffrey P Bombardier; Robert Fell; Reza Hakimelahi; Julian He; Margaret R Lentz; Jennifer Campbell; Elizabeth Curran; Elkan F Halpern; Eliezer Masliah; Susan V Westmoreland; Kenneth C Williams; R Gilberto González Journal: Magn Reson Med Date: 2011-03-04 Impact factor: 4.668
Authors: Douglas A Green; Eliezer Masliah; Harry V Vinters; Pouneh Beizai; David J Moore; Cristian L Achim Journal: AIDS Date: 2005-03-04 Impact factor: 4.177
Authors: R J Ellis; P Seubert; R Motter; D Galasko; R Deutsch; R K Heaton; M P Heyes; J A McCutchan; J H Atkinson; I Grant Journal: Neurosci Lett Date: 1998-09-18 Impact factor: 3.046
Authors: Eva-Maria Ratai; Sarah J Pilkenton; Jane B Greco; Margaret R Lentz; Jeffrey P Bombardier; Katherine W Turk; Julian He; Chan-Gyu Joo; Vallent Lee; Susan Westmoreland; Elkan Halpern; Andrew A Lackner; R Gilberto González Journal: BMC Neurosci Date: 2009-06-22 Impact factor: 3.288
Authors: C Paula Lewis-de Los Angeles; Paige L Williams; Yanling Huo; Shirlene D Wang; Kristina A Uban; Megan M Herting; Kathleen Malee; Ram Yogev; John G Csernansky; Sharon Nichols; Russell B Van Dyke; Elizabeth R Sowell; Lei Wang Journal: Brain Behav Immun Date: 2017-01-10 Impact factor: 7.217
Authors: Jaime H Vera; Qi Guo; James H Cole; Adriano Boasso; Louise Greathead; Peter Kelleher; Eugenii A Rabiner; Nicola Kalk; Courtney Bishop; Roger N Gunn; Paul M Matthews; Alan Winston Journal: Neurology Date: 2016-02-24 Impact factor: 9.910
Authors: Maria M Bednar; Christa Buckheit Sturdevant; Lauren A Tompkins; Kathryn Twigg Arrildt; Elena Dukhovlinova; Laura P Kincer; Ronald Swanstrom Journal: Curr HIV/AIDS Rep Date: 2015-06 Impact factor: 5.071